Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 18, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
4379
Shown on this page
12
Current sort
Recently updated
Condition scope
Lung Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings
NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Lung Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 469–480 of 4,379 matching trials for Lung Cancer.
Live ClinicalTrials.gov results.
Active filters: "small cell lung cancer" Clear condition filters
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

NCT04958811
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer
Interventions
Tiragolumab, Atezolizumab, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions
JZP815
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

NCT00632853
View directory record Official record
Conditions
Lung Cancer
Interventions
Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin
Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
930
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 575 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Suspended Phase 2 Interventional

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

NCT06014827
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Recruiting Phase 1 Interventional

A Study of KK2269 in Adult Participants With Solid Tumors

NCT06266299
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer
Interventions
KK2269, Docetaxel
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

NCT02259621
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Carboplatin, Paclitaxel, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Edmonds, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

NCT06269133
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
REGN2810, Platinum-doublet chemotherapy
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
BAY 3713372
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

NCT04514497
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567
View directory record Official record
Conditions
Small-Cell Lung Cancer
Interventions
Atezolizumab, Lurbinectedin, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Marietta, Georgia • Peoria, Illinois • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
12
States / cities
Duarte, California • Irvine, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 10:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

NCT01064648
View directory record Official record
Conditions
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
Interventions
Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
230
States / cities
Rogers, Arkansas • Antioch, California • Burbank, California + 148 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 10:23 AM EDT

About this Lung Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lung Cancer.